

Clinical Trials Registry at EDA

SN	Submission Date	Study Code (Specified as per the submitted protocol)	Sponsor/ CRO	Study Title	Study Phase (I, II, III, or IV)	Sites Activation Date “At which the clinical trials will be conducted in Egypt”	Status/Date: - Approved - Recruiting - Recruitment completion - Completed - Withdrawn - Suspended - Terminated	Conditions / Therapeutic Area	Interventions Used IMPs & its type (Biological, Pharmaceutical, Innovative, Herbal, or medical device)
1.	27/12/2018	M15-991	Sponsor: Abbvie	A multi-center, randomized, double-blind, placebo-controlled induction study to assess the efficacy and safety of Risankizumab in subjects with moderately to	III	1- CRC, Faculty of Medicine, Alexandria University/NA 2-Internal Medicine Department, Faculty of Medicine, Cairo University/NA	Approved 26/03/2019 Completed 03/11/2021	moderately to severely active Crohn's disease who failed prior biologic treatment	(Biological) Risankizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				severely active Crohn's disease who failed prior biologic treatment		3- MASRI CRC, Faculty of Medicine Ain Shams University/NA 4- National Hepatology and Tropical Medicine Institute (NHTMRI)/NA 5-Internal Medicine Department, Faculty of Medicine, Zagazig University/NA			
2.	27/12/2018	M16-000	Sponsor: Abbvie	A Multicenter, Randomized, Double Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of	III	1- Two sites at the Faculty of Medicine, CRC, Alexandria University (17/11/20219)	Approved 26/03/2019 Recruitment completion	Crohn's disease	(Biological) Risankizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease who responded to induction treatment in M16-006 or M15-991, or completed M15-989		2-National Hepatology and Tropical medicine Research institute (NHTMRI)/NA 3-Faculty of Medicine, Cairo University (22/10/2019) 4-MASRI CRC, Faculty of Medicine Ain Shams University (01/10/2019) 5- Faculty of Medicine, Zagazig University /NA			
3.	28/02/2019	M16-066	Sponsor: Abbvie	A Multicenter, Randomized, Double Blind, Placebo-Controlled 52-Week	III	1- CRC, Faculty of Medicine, Alexandria	Approved 10/06/2019	Ulcerative Colitis	(Biological) Risankizumab

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis		University (10/10/2019) 2- Air Force Specialized Hospital Research (02/10/2019) 3- National Liver Institute, Menoufia University (03/10/2019)	Recruitment completion		
4.	28/02/2019	M16-067	Sponsor: Abbvie	Multicenter randomized double-blind placebo-controlled induction study to evaluate the efficacy and safety of Risankizumab in subjects with moderately to	III	1- CRC, faculty of medicine, Alexandria University (02/2022) 2- National Liver Institute, Menoufia University (02/2022)	Approved 10/06/2019 Completed: 30/11/2023	Active ulcerative colitis.	(Biological) Risankizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				severely active ulcerative colitis.		3- Air Force Specialized Hospital (02/2022)			
5.	18/09/2019	ARTEMI S-DM "LPS1539 6"	Sponsor: SANOFI	A multicenter, multinational, prospective, interventional, single arm, Phase IV study evaluating the clinical efficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insulin	IV	1- Internal Medicine Department, CRC, Faculty of Medicine, Alexandria university/NA 2- Internal Medicine Department, Faculty of Medicine, Alexandria University/NA 3- GOTH/NA 4- Faculty of Medicine,	Approved 09/02/2020 Withdrawn	Type 2 diabetes mellitus	(Biological) Insulin glargine "Toujeo"

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						Menoufia University/NA 5- Internal Medicine Department, Faculty of Medicine, Ain Shams University /NA			
6.	18/11/2019	STAND	Sponsor: Novartis	A phase II, multicenter, randomized, open label, two arm study comparing the effect of crizanlizumab+ SOC alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to	II	1- Abu El Resh Children Hospital/NA	Approved 05/05/2020 Withdrawn 03/08/2021	Sickle cell anemia	(Biological) Crizanlizumab

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				sickle cell nephropathy					
7.	24/03/2020	STEAD FAST	Sponsor: Novartis	A Phase III, multicenter, double-blind study to assess efficacy and safety of two doses of crizanlizumab vs placebo with or without hydroxyurea / hydroxycarbamide therapy, in adolescent and adult sickle cell disease patients with vaso-occlusive crisis	III	1- Faculty of Medicine, Alexandria University/NA 2- Faculty of Medicine, Ain Shams University /NA	Approved 05/05/2020 Withdrawn 03/08/2021	Sickle cell anemia	(Biological) Crizanlizumab
8.	30/03/2020	WA40404	Sponsor: Roche	A Phase III b Multicenter, Randomized, double blind, Placebo-controlled study to evaluate the efficacy	IIIb	1-Sayed Galal Hospital/NA 2-Faculty of Medicine, Alexandria University/NA	Approved 23/08/2020 Withdrawn 25/08/2021	Primary progressive multiple sclerosis	(Biological) Ocrelizumab

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				and safety of Ocrelizumab in adults with primary progressive Multiple Sclerosis		3-MASRI CRC, Faculty of Medicine Ain Shams University/NA			
9.	14/09/2020	1368-0025	Sponsor: Boehringer Ingelheim	Open label long term extension study to assess the safety and efficacy of BI655130 treatment in patients with generalized pustular psoriasis	IIb	1- Dermatology department, Faculty of Medicine, Alexandria University Hospital/NA	Approved 18/05/2021 Withdrawn 31/10/2021	Generalized pustular psoriasis	(Biological) Spesolimab
10.	22/09/2020	CNBG202 0003SQ	Sponsor: China National Biotec Group company limited	Multicenter, Randomized, Double blind, parallel placebo controlled, Phase III clinical trial to evaluate the protective efficacy, safety and	III	Activation date: 09/2020 1- Vacsera Health Care Facility 2- Kameya Medical Center	Approved 28/03/2022 Completed 31/07/2022	COVID-19 Prophylaxis	(Biological) Inactivated SARS- COV-1 Vaccine

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

			Wuhan institute of biological products Co. Ltd Beijin institute of biological products Co.Ltd	immunogenicity of Inactivated SARS-COV-2 Vaccines in healthy population aged 18 years old and above					
11.	13/04/2021	D910DC0001 (Emerald-2)	Sponsor: AstraZeneca CRO: IQVIA	A phase 3 randomized double blind placebo controlled multicenter study of durvalumab monotherapy or in combination with bevacizumab as	III	1- CRC, Faculty of Medicine, Alexandria University (30/12/2021) 2- National Liver Institute, Menoufia University (08/11/2021)	Approved 12/12/2021 Recruitment completion	Hepatocellular carcinoma patients at high risk of recurrence after curative hepatic resection or ablation	(Biological) Durvalumab\ Bevacizumab

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				adjuvant therapy in patients with hepatocellular carcinoma who are at high risk of recurrence after curative hepatic resection or ablation		3- National Hepatology & Tropical Medicine Research Institute (08/11/2021) 4- Air Force Specialized Hospital (08/11/2021) 5- Clinical Oncology Department, Faculty of Medicine, Assiut University (11/11/2021) 6-Oncology Department, Faculty of Medicine, Mansoura			
--	--	--	--	--	--	--	--	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						University (13/12/2021) 7-MASRI CRC, Faculty of Medicine, Ain Shams University (17/11/2021) 8-National Cancer Institute (08/11/2021)			
12.	19/05/2021	01- Sputnik- Light- 2021	Sponsor: Human vaccine LLC (Global), Russian ministry of healthcare –	A phase III, randomized, double- blind, placebo- controlled international multi- site clinical trial in parallel assignment to evaluate efficacy, immunogenicity and safety of the Sputnik Light vector vaccine	III	Activation date: Dec 2022 1- National hepatology and tropical medicine center 2- Katameya Medical Center	Approved 24/08/2021 Completed: 31/08/2022	COVID-19 Prophylaxis	(Biological) Sputnik Light vector vaccine

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

			Gamalya (Local) CRO: PDC	in adults in the SARS-Cov-2 infection prophylactic treatment					
13.	25/05/2021	KATE-3	Sponsor: Roche	A randomized, multi center, double blind, placebo-controlled phase III study of the efficacy and safety of Trastuzumab Emtansine in combination with Atezolizumab or placebo in Pts with HER2-positive and PD-L1- positive locally advanced or metastatic breast cancer who have	III	1- NEMROCK, Faculty of Medicine, Kasr Al- Ainy Hospital, Cairo University /NA 2- Shefaa Al- Orman Hospital/NA 3- Baheya Hospital /NA	Approved 05/12/2021 Withdrawn 19/12/2022	HER2- positive and PD-L1- positive locally advanced or metastatic breast cancer	(Biological) Trastuzumab Emtansine/ Atezolizumab

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				received prior Trastuzumab + Atezolizumab and Taxane- based therapy					
14.	18/08/2021	MO42541	Sponsor: Roche CRO: IQVIA for Monitoring	A phase III, open label, randomized study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or sorafenib alone in hepatocellular carcinoma previously treated with Atezolizumab and Bevacizumab	III	1- Air Force Specialized Hospital (17/01/2024)	Approved 02/02/2022 Recruitment completion	Hepatocellul ar carcinoma	(Biological) Atezolizumab/ Lenvatinib/ Sorafenib
15.	02/09/2021	COVID_ VACC_1	Sponsor: National	A Phase 1 Clinical Trial to Evaluate the Safety,	I	1- National Research Center (11/11/2021)	Approved 09/11/2021	Covid-19 Prophylaxis	(Biological)

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			research center	Tolerability, and Immunogenicity of Inactivated SARS-CoV-2 Vaccine Against COVID-19 in Healthy Adults			Suspended 09/12/2021		Inactivated SARS-CoV-2 Vaccine
			CRO: Clinmax						
16.	17/01/2022	SPHINX-EGYPT SPHINX2 2122020	Sponsor: - EVA PHARMA - VSVRI - supreme council of university hospitals - Ministry of higher education and scientific research	Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of SARS-CoV-2 Infection (COVID-19)	I	Al-Manial Specialized University Hospital, Cairo University Hospitals (06/02/2022)	Approved 03/02/2022 Completed 30/04/2023	Covid-19 Prophylaxis	(Biological) EgyVax

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			CRO: Dataclin						
17.	04/11/2021	GBT2104-131	Sponsor: Global blood therapeutics Inc. \ Pfizer CRO: MCT	A randomized double blinded placebo controlled multicentre study to access the safety and efficacy of Inclacumab in participants with sickle cell disease experiencing Vaso-occlusive crisis	III	1-Pediatric Department, Faculty of Medicine, Mansoura University/NA 2-Pediatric Department, Faculty of Medicine, Zagazig University (28/02/2023) 3- MASRI-CRC, Faculty of Medicine, Ain Shams University (04/03/2023) 4-Pediatric Hematology	Approved 14/06/2022 Completed: 30/05/2025	sickle cell disease patients with Vaso-occlusive crisis	(Biological) Inclacumab

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						Department& CRC, Faculty of Medicine, Alexandria University/NA 5- Abo El-Resh Hospital &CRC, Faculty of Medicine, Cairo University and Hematology Department, (28/02/2023)			
18.	04/01/2022	GBT2104-132	Sponsor: Global blood therapeuti cs Inc.\ Pfizer	A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re- admission in	III	1-Pediatric Department, Faculty of Medicine, Mansoura University/NA 2-Pediatric Department, Faculty of Medicine,	Approved 14/06/2022 Withdrawn 29/06/2023	Sickle cell disease patients with Vaso- occlusive crisis	(Biological) Inclacumab

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			CRO: MCT	Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises (GBT-132)		Zagazig University/NA 3- MASRI, CRC, Faculty of Medicine Ain Shams University/NA 4-Pediatric Hematology Department, CRC, Faculty of Medicine, Alexandria University/NA 5- CRC, Faculty of Medicine, Cairo University and Hematology Department, Abo El- Resh Hospital/NA			
19.	28/11/2021	GBT2104- 133	Sponsor: Global blood	An Open-label Extension Study to Evaluate the Long-	III	1-Pediatric Department, Faculty of Medicine,	Approved 14/06/2022	sickle cell disease	(Biological)

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			therapeutics Inc.\ Pfizer	term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial		Mansoura University/NA 2- Pediatric Department, Faculty of Medicine, Zagazig University/NA 3- MASRI, CRC, Faculty of Medicine Ain Shams University/NA 4-Pediatric Hematology Department& CRC, Faculty of Medicine, Alexandria/NA University Hospital 5- Abo El-Resh Hospital &CRC, Faculty of Medicine, Cairo University and	Withdrawn 17/12/2023		Inclacumab/ Placebo
--	--	--	------------------------------	---	--	--	-------------------------	--	------------------------

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						Hematology Department/NA			
20.	08\06\2022	Consonance- MN39159	Sponsor: F. HOFFMAN- LA ROCHE LTD CRO: IQVIA (for monitoring activities only)	An open-label, single-arm 4-year study to evaluate effectiveness and safety of ocrelizumab treatment in patients with progressive multiple sclerosis	III	1- CRC, Faculty of Medicine, Alexandria University (05/03/2019) 2- MASRI-CRC, Faculty of Medicine, Ain Shams University (25/02/2021)	Approved 20/09/2022 Recruitment completion	Progressive multiple sclerosis	(Biological) Ocrelizumab
21.	14/08/2022	CAIN457 A2310	Sponsor: Novartis CRO: MCT	A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate	III	1- CRC, Faculty of Medicine, Alexandria University Hospital (11/01/2017)	Approved 04/12/2022 Early terminated by the sponsor	Treatments of severe chronic plaque psoriasis	(Biological) Secukinumab

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				efficacy of subcutaneous Secukinumab compared to placebo and etanercept (in a single blinded arm) after twelve weeks of treatment, and to assess the safety, tolerability, and long-term efficacy in subjects from 6 to less than 18 years of age with severe chronic plaque psoriasis		2- Dermatology Department, Faculty of Medicine, Ain Shams University Hospital (22/01/2017)	31/03/2023		
22.	19/12/2022	Recbio	Sponsor : Jiangsu Recbio	A multi-center randomized double blind placebo-controlled phase 2/3	II/III	1.Egyptian CDC 2.Katameya Medical Center	Refusal by EDA: 20/04/2022	Prophylactic Vaccine for COVID-19	(Biological) Recombinant two component COVID-19 vaccine

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			Technology Co., Ltd	trial to evaluate the efficacy, safety and immunogenicity of the recombinant two component COVID-19 vaccine (CHO) cell in adult aged 18 years and older		3.National Hepatology and Tropical Medicine Research Institute (NHTMRI)			
			CRO: PDC						
23.	06/06/2023	FUZION CNTO195 9CRD	Sponsor: Janssen Research and Development CRO: MCT	A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn's Disease "FUZION CD"	III	1- National Hepatology and Tropical Medicine Research Institute (NHTMRI)/ (09/12/2024) 2- CRC, Faculty of Medicine, Alexandria University (09/12/2024) 3- Department of Internal Medicine,	Approved 13/08/2023 Recruiting	Fistulizing perianal Crohn's disease	Guselkumab (Biological)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						Kasr Al Aini Hospital, Cairo University (09/12/2024) 4- MASRI CRC, Faculty of Medicine, Ain Shams University (09/12/2024)			
24.	14/05/2023	MP- ADA1-01	Sponsor: Minapharm CRO: CRS Clinical Research Services Berlin GmbH	A Phase I, randomized, double-blind, 2- arm, parallel group trial to compare pharmacokinetics of Adessia with EU-authorized Humira in healthy male and female participants"	I	1- CRS clinical research services, Berlin GmbH/NA 2- CRS clinical research services, Mannheim GmbH/NA	Approved 10/08/2023 Completed: 17/11/2023	Inflammatory disease (Biosimilar to Humira)	Adessia (Biological)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

25.	04/05/2023	MOM-M281-006	Sponsor: Janssen Research and Developm ent CRO: MCT	Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study with a Long- term Open-label Extension”	II/III	1- National Cancer Institute, Cairo University (13/03/2024) 2- Oncology center, Mansoura University Hospital (13/03/2024) 3- Department of Internal Medicine, Kasr Al Eini Hospital, Cairo University (13/03/2024) 4- Naser Institute Hospital for Research and Treatment (13/03/2024) 5- CRC, Faculty of Medicine,	Approved 19/07/2023 Early Terminated by the sponsor 21/02/2025	Warm Autoimmune Hemolytic Anemia	M281 (Biological)
-----	------------	--------------	--	---	--------	---	---	---	--------------------------

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

						Alexandria University (13/03/2024) 6- MASRI CRC, Faculty of Medicine, Ain Shams University (13/03/2024)			
26.	09\10/2023 shift to amendment submission 26\12\2023	EMERAL D-3) D910VC0 0001	Sponsor: AstraZeneca CRO: IQVIA	A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared	III	1- Oncology Department &CRC, Faculty of Medicine, Alex University/NA 2- National Hepatology and Tropical Medicine Research Institute (NHTMRI) (09/06/2024)	Approved 08/02/2024 Recruiting	Locoregional Hepatocellular Carcinoma	(Biological) Durvalumab / Tremelimumab/ Lenvatinib /TACE

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)		3- Egyptian Liver Hospital (13/06/2024) 4-National Liver Institute, Menoufia (25/01/2024)			
27.	14/12/2023	BCD-178	Sponsor: JSC BIOCAD CRO: Dataclin	A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer	III	1-Clinical Oncology Department, Faculty of Medicine, Alexandria University Hospital/NA 2- Clinical Oncology Department, Faculty of Medicine, Cairo University Hospital/NA	Approved: 22/04/2024 Withdrawn: 25\12\2024	Her-2 positive breast cancer	Biological BCD-178

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

28.	08/01/2024	SerpinPc 102	Sponsor: Apcintex CRO: MCT	A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects with Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (AP-0102)	Iib	1- MASRI CRC, Faculty of Medicine, Ain Shams University/NA	Conditional Approved 13/06/2024 Final Approval 31/10/2024 Withdrawn: 16/01/2025	Hemophilia A or Moderately Severe to Severe Hemophilia B	Biological SerpinPC 102
29.	08/01/2024	SerpinPC1 03	Sponsor: Apcintex CRO: MCT	A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in Subjects with Hemophilia B with Inhibitors (AP-0103)	Iib	1- MASRI CRC, Faculty of Medicine Ain Shams University/NA	Conditional Approved 13/06/2024 Final Approval 31/10/2024 Withdrawn: 16/01/2025	Hemophilia B with Inhibitors	Biological Serp PC 103

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

30.	08/02/2024	D9185C00 001'' TILIA'	Sponsor: AstraZenca CRO: IQVIA	A Phase III, Multicenter, Randomized, Double-bind, Parallel-group, Placebo-Controlled study to evaluate the efficacy and safety of Tozorakimab (MEDI3506) in patients hospitalized for viral lung infection requiring supplemental oxygen	III	1- Chest Disease Department, Air Force Specialized Hospital/NA 2- MASRI CRC, Faculty of Medicine Ain Shams University/NA 3- Chest Department, CRC, Faculty of Medicine, Alexandria University/NA	Conditional approval: 04/08/2024 Withdrawn: 30/01/2025	Patients hospitalized for viral lung infection	Biological Tozorakimab
31.	16/01/2025	GA45329- Ametrine 1	Sponsor: Roche	A Phase III, Multicenter,	III	1- Internal Medicine,	Approved: 10/03/2025	Patients with Moderately	Biological

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Double-Blind, Placebo- Controlled, Treat- Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 In Patients with Moderately to Severely Active Ulcerative Colitis		Department& CRC, Faculty of Medicine, Alexandria University/NA	Withdrawn: 10/09/2025	to Severely Active Ulcerative Colitis	RO7790121
32.	16/01/2025	GA45330- Ametrine 2	Sponsor: Roche	A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction	III	1- Internal Medicine Department& CRC, Faculty of Medicine, Alexandria University/NA	Approved: 10/03/2025 Withdrawn: 10/09/2025	Patients with Moderately to Severely Active Ulcerative Colitis	Biological RO7790121

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Therapy with RO7790121 In Patients with Moderately to Severely Active Ulcerative Colitis					
33.	11\05\2025	GA45331 SEBRITE-1	Sponsor: Roche	A Phase III Multicenter Double Blind Placebo Controlled Treat through study to assess the efficacy and safety of Induction and Maintenance therapy with RO7790121 in patients with moderately to severely active Crohn's disease	III	1- Gastroenterology Department& CRC, Faculty of Medicine, Alexandria University/NA 2- Gastroenterology, Air Force Specialized Hospital/NA 3- Hepatology Department, National Liver Institute,	Approved: 01/06/2025 Withdrawn 23/06/2026	Crohn's Disease	Biological RO7790121

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						Menoufia University/NA			
34.	20/05/2025	M20-465	Sponsor: Abbvie	A Phase III Multicenter, Randomized, Double- Blind Placebo- Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa	III	1- Dermatology Department, Air Force Specialized Hospital/NA 2- Dermatology, Andrology and Venerology Department& CRC, Faculty of Medicine, Alexandria University/NA 3- MASRI CRC, Faculty of Medicine, Ain Shams University/NA	Approved: 08/10/2025 Withdrawn 17/03/2026	Moderate to Severe Hidradenitis Suppurativa	Biological Lutikizumab

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

35.	18/09/2025	GA45332 SEBRITE-2	Sponsor: Roche	A Phase III, Multicenter, Double- Blind, Placebo- Controlled Study to assess the efficacy and safety of induction therapy with RO7790121 in patients with moderately to severely active Crohn's disease	III	1- Gastroenterology Department & CRC, Faculty of Medicine, Alexandria University/NA 2- Gastroenterology Department, CRC Air Force Specialized Hospital/NA 3- Hepatology Department, National Liver Institute, Menoufia University/NA	Approved: 20/10/2025 Withdrawn 23/06/2026	Crohn's Disease	Biological RO7790121
36.	24/10/2025	221530/JA DE	Sponsor: GSK CRO: MCT	A Randomized, Double-Blind, Placebo Controlled Phase III Study to	III	1- MASRI CRC, Faculty of Medicine Ain	Approved: 04/05/2026	Locally Advanced Unresected Head and	Biological Dostarlimab

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Evaluate Dostarlimab as Sequential Therapy After Chemoradiation In Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma		Shams University/NA 2- Clinical Oncology Department& CRC Faculty of Medicine, Alexandria University/NA 3- Clinical Oncology Department, Faculty of Medicine, Mansoura University Hospital/NA 4- Clinical oncology department, Nasser Institute for Research and Treatment/NA		Neck Squamous Cell Carcinoma	
--	--	--	--	--	--	---	--	------------------------------	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						5- Clinical Oncology Department, Faculty of Medicine, Assiut University Hospital/NA			
37.	17/12/2020	CEGA230 B2404	Sponsor: Novartis CRO: MCT	A Phase IV Multicenter Open Label Study to Determine the Safety, Tolerability and Clinical Outcomes Following Oral Administration of Egaten (Triclabandazole) in patients 6 Years of Age or Older with Fascioliasis (Egaten)	IV	1-Pediatric Hepatology Unit, Abu El Rich Al Mounira Children Hospital, Cairo University (11/01/2023). 2-CRC, Faculty of Medicine, Alexandria University (25/01/2023)	Approved 12/04/2021 Completed 11/12/2025	Fascioliasis	(Pharmaceutical) Triclabandazole (Egaten)

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

38.	-----	CLEE011 A3201C RIGHT Choice	Sponsor: Novartis CRO: MCT	A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate with Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients with Hormone Receptor- Positive/HER2- Negative Inoperable Locally Advanced or Metastatic Breast Cancer - RIGHT Choice Study (RIGHT Choice)	II	1- MASRI CRC, Faculty of Medicine, Ain Shams University, (28/01/2020). 2- Baheya Hospital Research Center (19/01/2020) 3- NEMROC, Kasr Al Aini Hospital, Cairo University (05/03/2020) 4- Nasser Institute Cancer Center (26/03/2020)	Approved 08/01/2020 Completed 08/01/2023	HER-2 Negative Breast Cancer	(Pharmaceutical) Ribociclib Plus Goserelin / Physician Choice Chemotherapy
-----	-------	--------------------------------------	---	--	----	---	---	---------------------------------------	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

39.	06/04/2021	CLJN452 D12201C	Sponsor: Novartis CRO: MCT	A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Assess Efficacy, Safety and Tolerability of Oral Tropifexor (LJN452) and Licogliflozin (LIR066) Combination Therapy Compared to Each Monotherapy for Treatment of Adult Patients with Non- Alcoholic Steatohepatitis (NASH) and Liver Fibrosis ELIVATE	III	1- National Hepatology and Tropical Medicine Research Institute (NHTMRI)/NA 2- Egyptian Liver Research Institute and Hospital (ELRIAH)/NA	Approved 09/11/2021 Withdrawn 20/11/2022	Treatment of Adult Patients with Non- Alcoholic Steatohepatitis (NASH) and Liver Fibrosis	(Pharmaceutical) Tropifexor (LJN452) and Licogliflozin (LIR066) Combination Therapy
-----	------------	--------------------	---	---	-----	---	---	---	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

40.	06/07/2021	MK4482-002	Sponsor: MSD	A Phase 2/3, Randomized Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of MK-4482 In Non-Hospitalized Adults with COVID-19	II/III	1- Abbasya Chest Hospital (21/09/2021) 2- Helwan Fever Hospital (22/09/2021) 3- Imbaba Fever Hospital/NA 4- Abbasya Fever Hospital (20/09/2021) 5- National Hepatology and Tropical Medicine Research Institute (NHTMRI) (22/09/2021) 6- National Center for Allergies and Chest, Imbaba (22/09/2021)	Approved 08/08/2021 Completed 05/05/2022	Non-Hospitalized Adults with COVID-19	Pharmaceutical (Molnupiravir)
-----	------------	------------	--------------	---	--------	--	---	---------------------------------------	-------------------------------

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

41.	03/08/2021	Mol_0607 202	Sponsor: EVA Pharma	A Multi-Centre, Two-Arm, Parallel Group, Randomized, Double-Blinded, Phase III Trial to Assess Efficacy and Safety of Molpravir in Treatment of Patients with Mild to Moderate COVID-19 Infection	III	1- Alexandria Fever Hospital/NA 2- National Hepatology and Tropical Medicine Research Institute (NHTMRI)/NA 3- Fayoum General Hospital/NA 4- Abbasya Chest Hospital/NA 5- CDC, Imbaba Hospital/NA	Refused 17/04/2022	Mild to Moderate COVID-19 Infection	Pharmaceutical (Molnupiravir)
42.	24/10/2021	M14-430	Sponsor: Abbvie	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and	III	1- CRC Air Force Specialized Hospital (28/01/2019). 2- National Liver Institute Menoufia University (21/01/2019).		Chron's Disease	(Pharmaceutical) Upadacitinib/ matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease Who Completed the Studies M14-431 or M14-433		3- CRC, Faculty of Medicine, Alexandria University (05/02/2019). 4- MASRI CRC, Faculty of Medicine, Ain Shams University (25/10/2020). 5- National Hepatology and Tropical Medicine Research Institute (NHTMRI) (29/01/2019).			
43.	-----	BO40336 ALINA	Sponsor: Roche	A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant	III	1- NEMROCK, Kasr Al Aini Hospital, Cairo University (19/09/2019).	Approved 29/05/2019 Recruitment Completion	Lung Cancer	(Pharmaceutical) Alectinib / Platinum-based Chemotherapy

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Alectinib Versus Adjuvant Platinum- Based Chemotherapy in Patients with Completely Resected Stage Ib (Tumors ≥ 4 Cm) To Stage IIIa Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALINA)					
44.	12/12/2021	Cl_Tr_17 122019 MIRACL E-ALA	Sponsor: EVA Pharma CRO: MARC	A Multicenter, Interventional, Two- Arm, Parallel- Group, Randomized, Double-Blinded, Placebo-Controlled,	IV	1- Diabetes, Metabolism, and Lipidology Unit, Department of Internal Medicine, Alexandria	Approved 12/10/2022 Completed 11/12/2024	Treatment of Symptomatic Diabetic Polyneuropat hy	(Pharmaceutical) Alpha-Lipoic Acid (Thiotacid)/ matching placebo

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Phase IV Trial to Evaluate the Efficacy of Alpha-Lipoic Acid in the Treatment of Patients with Symptomatic Diabetic Polyneuropathy in Egypt (MIRACLE-ALA)		University Hospital (27/10/2022). 2- Department of Internal Medicine, Ain Shams University Hospital (01/12/2022). 3- Department of Internal Medicine, Menoufia University Hospital (29/01/2023). 4- Department of Internal Medicine, Intrinsic Specialized Hospital, Mansoura University, (09/01/2023). 5- Department of Internal Medicine,			
--	--	--	--	---	--	---	--	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						Diabetes and Endocrinology Unit, Beni-Suef University Hospital, (03/04/2023).			
45.	12/12/2021	MK4482-013 MOVE-Ahead	Sponsor: MSD	A Phase 3 Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory Confirmed SARS-COV 2 Infection with Symptoms) in Adults. (MOVE-Ahead)	III	1- MASRI CRC, Faculty of Medicine, Ain Shams University (22/03/2022). 2- CRC Air Force Specialized Hospital (22/03/2022). 3- National Hepatology and Tropical Medicine Research Institute (NHTMRI) (22/03/2022).	Approved 18/01/2022 Completed 16/11/2022	Prophylaxis of COVID-19	(Pharmaceutical) Molnupiravir/ matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						4- Imbaba Fever Hospital (30/05/2022). 5- National Center for Allergies and Chest Imbaba (30/05/2022).			
46.	30/03/2022	GBT440-032	Sponsor: GBT (Subsidiary of Pfizer) CRO: CTI	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease (HOPE Kids 2)	III	1- MASRI CRC, Faculty of Medicine, Ain Shams University, (26/01/2021) 2- CRC, Faculty of Medicine Alexandria University (27/01/2021). 3- Pediatrics Hematology Department, Abu El Rich Al Mounira	Approved 31/07/2022 IMP Dosing Pause 02/05/2024 Early Termination by the sponsor 29/09/2024	Sickle Cell Disease	(Pharmaceutical) Voxelotor/ matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						Children Hospital, Cairo University (25/01/2021). 4- Pediatrics Hematology Department, Zagazig University Hospital (31/01/2021).			
47.	18/04/2022	GBT440-034	Sponsor: GBT (Subsidiary of Pfizer) CRO: IQVIA	An Open Label Extension Study of GBT440 Administered Orally to Patients with Sick Cell Disease who Have Participated in GBT440 Clinical Trials	III	1- Pediatrics Hematology Department, Abu El Rich Al Mounira Children Hospital, Cairo University (16/04/2019). 2- MASRI CRC, Faculty of Medicine, Ain Shams University (15/04/2019).	Approved 02/08/2022 Early Termination by the sponsor 30/09/2024	Sickle Cell Disease	(Pharmaceutical) Voxelotor

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						3- CRC, Faculty of Medicine, Alexandria University, Site I (20/04/2019) Site II (18/04/2019) 4- Pediatrics Hematology Department Zagazig University Hospital (14/04/2019).			
48.	17/05/2022	F901318/0032	Sponsor: F2G CRO: IQVIA	Open Label Single Arm Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Seedosporium	Iib	1-Department of Internal Medicine, Oncology Center, Mansoura University Hospital (27/05/2021). 2- CRC, Faculty of Medicine, Alexandria	Terminated (By Sponsor) 24/07/2022	Invasive Fungal Infection	(Pharmaceutical) Olorofim

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Spp., Aspengillus Spp., & other Resistant Fungi in Patients Lacking Suitable Alternative		University (06/06/2021). 3-Naser Institute Hospital for Research and Treatment/NA 4- MASRI CRC, Faculty of Medicine, Ain Shams University (04/04/2021). 5- CRC, Air Force Specialized Hospital (19/06/2021). 6-National Cancer Institute (05/04/2021). 7- Department of Internal Medicine, Kasr Al Aini			
--	--	--	--	---	--	---	--	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						Hospital, Cairo University (02/08/2021).			
49.	12/06/2022	CLSYN.1702 (OASIS-9)	Sponsor: Hamilton Health Science CRO: Clinmax	A 2x2 Factorial Randomized Controlled Trial of Colchicine and spironolactone in Patients With myocardial infarction/SYNERGY Stent Registry – Organization to Assess Strategies for Ischemic Syndromes 9 (OASIS-9)	III/IV	1- Cardiology Department, Mansoura University Hospital (25/09/2022). 2-Cardiology Department, Suez Canal University Hospital (24/09/2022). 3- Cardiology Department, Fayoum General Hospital, (20/09/2022). 4- Cardiology Department, Tamia Central Hospital, (20/09/2022).	Approved 24/07/2022 Completed 01/08/2024	STEMI/Non-STEMI Myocardial Infarction	(Pharmaceutical) Colchicine, Spironolactone/ matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						5- Cardiology Department, El Kharga Specialized Hospital (28/09/2022). 6-National Heart Institute (26/09/2022)			
50.	15/06/2022	20140106	Sponsor: Onyx Pharmaceuticals (Subsidiary of Amgen) CRO: IQVIA	Phase 1b/2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia	Ib/II	1- CRC, Children Cancer Hospital Egypt /NA	Approved 23/08/2022 Withdrawn 19/06/2023	Relapsed or Refractory Acute Lymphoblastic Leukemia	(Pharmaceutical) Carfilzomib
51.	18/07/2022	AG348-C-020	Sponsor: Agios	A Phase 2/3, Double-Blind, Randomized, Placebo-	II/III	1- CRC, Faculty of Medicine, Alexandria University /NA	Approved 27/09/2022 Withdrawn	Sickle Cell Disease	(Pharmaceutical) Mitapivat / matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			CRO: MCT	Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects with Sickle Cell Disease		2- Pediatric Hematology Department, Zagazig University Hospital, /NA 3- CRC, Faculty of Medicine, Cairo University /NA 4- Pediatrics Hematology Department, Abu El Rich Al Mounira Children Hospital, Cairo University /NA 5- Pediatric Hematology Department, Mansoura University Hospital /NA	21/08/2023		
--	--	--	-------------	---	--	---	------------	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						6- MASRI CRC, Faculty of Medicine, Ain Shams University /NA			
52.	26/07/2022	F901318/0 041	Sponsor: F2G CRO: IQVIA	A Phase III, Adjudicator- Blinded, Randomized Study to Evaluate the Efficacy and Safety of Treatment with Olorofim Versus Treatment with Ambisome® Followed by Standard of Care (SOC) in Patients with Invasive Fungal Disease	III	1- Oncology Center, Mansoura University/NA 2- CRC, Faculty of Medicine, Alexandria University /NA 3- Air Force Specialized Hospital CRC /NA 4- MASRI CRC, Faculty of Medicine, Ain Shams University, /NA	Approved 11/10/2022	Invasive Fungal Disease caused by Aspergillus species	(Pharmaceutical) Olorofim / Ambisome

Color	Green	Biological
Indicator	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				(IFD) Caused by Aspergillus Species		5- Oncology Department, Faculty of Medicine, Zagazig University Hospital /NA 6- National Cancer Institute /NA 7- CRC, Faculty of Medicine, Cairo University /NA 8- Nasser Institute for Research and Treatment /NA			
53.	27/07/2022	APD334-202	Sponsor: Arena Pharmaceuticals (Subsidiary of Pfizer)	A Multicenter Randomized Double Blinded Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod	III	1- CRC, Faculty of Medicine, Alexandria University, (22/06/2021).	Approved 23/08/2022 Recruitment Completion	Moderately to Severe Active Crohn's Disease	(Pharmaceutical) Etrasimod / matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				as Induction and Maintenance Therapy for Moderately to Severe Active Crohn's Disease (Etrasimod)		2- CRC Air Force Specialized Hospital (21/06/2021). 3-National Liver Institute, Menoufia University (20/06/2021). 4-National Hepatology and Tropical Medicine Research Institute (NHTMRI) (27/06/2021). 5- Integrated Clinical and Research Center for Intestinal Disorders (ICRID), Cairo University (23/06/2021).	Early Terminated by the sponsor 20/03/2025		
--	--	--	--	--	--	--	--	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						6-Egyptian Liver Research Institute and Hospital (15/06/2021). 7- MASRI CRC, Faculty of Medicine, Ain Shams University (16/06/2021). 8-Theodor Bilharz Research Institute (11/07/2021).			
54.	07/08/2022	EFC17215 LEAP-2-MONO	Sponsor: Sanofi	A Phase 3, Multicenter, Multinational Randomized Double-Blind Double-Dummy, Active Comparator Study to Evaluate the Efficacy and	III	1- CRC, Faculty of Medicine, Alexandria University /NA	Approved 24/10/2022	Gaucher Disease Type 3 (GD3)	(Pharmaceutical) Venglustat/ Cerezyme

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Safety of Venglustat in Adult and Pediatric Patients with Gaucher Disease Type 3 (GD3) who Have Reached Therapeutic Goals with Enzyme Replacement Therapy (LEAP-2-MONO)					
55.	15/08/2022	AG348-C-017	Sponsor: Agios CRO: MCT	A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects with Non–	III	1-Pediatrics Hematology Department, Abu El Rich Al Mounira Children Hospital, Cairo University /NA	Approved 02/11/2022 Withdrawn 26/06/2023	Non-Transfusion-Dependent Alpha or Beta Thalassemia	(Pharmaceutical) Mitapivat / matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Transfusion-Dependent Alpha-or Beta-Thalassemia (ENERGIZE)		2- CRC, Faculty of Medicine, Cairo University /NA 3- MASRI CRC, Faculty of Medicine, Ain Shams University/NA			
56.	15/08/2022	AG348-C-018	Sponsor: Agios CRO: MCT	A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects with Transfusion-Dependent Alpha-or Beta-	III	1-Pediatrics Hematology Department, Abu El Rich Al Mounira Children Hospital, Cairo University /NA 2- CRC, Faculty of Medicine, Cairo University /NA 3- MASRI CRC, Faculty of Medicine, Ain	Approved 02/11/2022 Withdrawn 26/06/2023	Transfusion-Dependent Alpha or Beta Thalassemia	(Pharmaceutical) Mitapivat / matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Thalassemia (ENERGIZE-T)		Shams University, /NA			
57.	29/08/2022	4202- HEM-301	Sponsor: Forma Therapeutics CRO: MCT	An Adaptive, Randomized, Placebo- Controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (Hibiscus Study)	III	1- CRC, Faculty of Medicine Alexandria University (12/08/2024). 2- Pediatric Hematology Department, Zagazig University Hospital (31/07/2024) 3- CRC, Faculty of Medicine, Cairo University (07/07/2024). 4- Pediatrics Hematology Department, Abu El Rich Al	Approved 11/12/2022 Recruitment Completion	Sickle Cell Disease	(Pharmaceutical) Etavopivat / matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						Mounira, Cairo University (31/07/2021). 5- MASRI CRC, Faculty of Medicine, Ain Shams University (07/07/2024)			
58.	29/09/2022	GO42784 LIDERA	Sponsor: Roche CRO: MCT	A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in	III	1- CRC, Faculty of Medicine, Alexandria University (24/05/2023). 2-Medical Research Institute, Alexandria University (03/04/2023). 3-Oncology Center, Mansoura	Approved 04/12/2022 Recruitment Completion	Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer	(Pharmaceutical) Giredestrant / Physician Choice of Adjuvant Endocrine Monotherapy

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Patients with Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer (LIDERA)		University (03/04/2023) 4- NEMROCK, Kasr Al Ainy Hospital, Cairo University (13/04/2023) 5- Oncology Department, El Demerdash Hospital, Ain Shams University (08/05/2023). 6- Gustave Roussy International Hospital (05/06/2023). 7- Sohag Oncology Center (05/06/2023)			
--	--	--	--	---	--	--	--	--	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

59.	16/11/2022	(ACTIV-2D/A5407)	Sponsor: Shionogi CRO: IQVIA	A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared with Placebo in Non-Hospitalized Participants with COVID-19 (ACTIVE)	III	1-National Hepatology and Tropical Medicine Research Institute (NHTMRI) /NA 2- MASRI CRC, Faculty of Medicine, Ain Shams University /NA 3-CRC, Faculty of Medicine, Alexandria University /NA 4- CRC Air Force Specialized Hospital /NA 5-National Institute for Chest Allergy and Diseases /NA	Approved 31/01/2023 Withdrawn 26/09/2023	Covid-19 treatment	(Pharmaceutical) S-217622 / matching placebo
-----	------------	------------------	---	--	-----	---	---	--------------------	---

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						6-Imbaba Fever Hospital /NA			
60.	28/11/2022	RBSC216 1	Sponsor: Salix pharmaceuticals CRO: IQVIA	A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell Disease	Ila	1-Pediatric Hematology Department, Abu El Rich Al Mounira Children Hospital, Cairo University /NA 2- MASRI CRC, Faculty of Medicine, Ain Shams University /NA 3- Pediatric Hematology Department, Faculty of Medicine, Zagazig University Hospital /NA	Approved 05/02/2023 Withdrawn 06/11/2023	Sickle Cell Disease	(Pharmaceutical) Rifaximin / matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						4-CRC, Cairo University /NA 5- CRC, Faculty of Medicine, Alexandria University /NA			
61.	22/01/2023	AT/03A-017	Sponsor: Atea Pharmaceuticals CRO: Avicemer	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19	III	1- National Hepatology and Tropical Medicine Research Institute (NHTMRI) /NA	Approved: 15/10/2023 Withdrawn 07/04/2024	COVID-19	(Pharmaceutical) Bemnifosbuvir/matching Placebo
62.	13/02/2023	ENRICH-AF	Sponsor: Hamilton Health Science	Edoxaban for Intracranial Haemorrhage Survivors with	IV	1- MASRI CRC, Faculty of Medicine, Ain Shams University	Approved 10/05/2023	Atrial Fibrillation in patients with previous	(Pharmaceutical) Edoxaban

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			CRO: Clinmax	Atrial Fibrillation (ENRICH- AF)		(10/09/2020). 2- Neurology Department, Faculty of Medicine, Zagazig University Hospital (21/05/2021). 3-Neurology Department, Fayoum General Hospital (15/09/2020). 4- Neurology Department, Faculty of Medicine, Tanta University Hospital, (27/10/2020) 5-Neurology Department, Faculty of Medicine, Mansoura University	Recruitment Completion	Intracranial Haemorrhage	
--	--	--	-----------------	-------------------------------------	--	---	---------------------------	-----------------------------	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

						Hospital (19/10/2020). 6- CRC, Faculty of Medicine, Alexandria University, (09/11/2020) 7- Neurology Department, Faculty of Medicine Assiut University Hospital (30/04/2022).			
63.	13/02/2023	GBT440-038	Sponsor: GBT (Subsidiary of Pfizer)	An Open-Label Extension Study of Voxelotor Administered Orally to Paediatric Participants with Sickle Cell Disease Who Have Participated in	III	1-CRC, Faculty of Medicine, Alexandria University (29/01/2024). 2- Pediatrics Hematology Department, Faculty of Medicine,	Approved 30/03/2023 IMP Dosing Pause 02/05/2024	Sickle Cell Disease	(Pharmaceutical) Voxelotor

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Voxelotor Clinical Trials		Zagazig University Hospital (10/12/2023). 3-Pediatrics Hematology Department, Abu El Rich Al Mounira Children Hospital, Cairo University (13/03/2024) 4- MASRI CRC, Faculty of Medicine, Ain Shams University (21/02/2024).	Early Terminated by the Sponsor 26/09/2024		
64.	01/03/2023	GN41851 FENHANC E	Sponsor: Roche	A Phase III Multicentre, Randomized, Double-Blind, Double-Dummy, Parallel-Group	III	1-CRC, Faculty of Medicine, Alexandria University/NA	Approved 26/4/2023 Withdrawn 11/01/2024	Relapsing multiple sclerosis	(Pharmaceutical) Fenebrutinib/ Teriflunomide/ matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis. (FENHANCE)					
65.	06/03/2023	1305-0023 (FIBRONER-ILD)	Sponsor: Boehringer Ingelheim CRO: IQVIA	A Double Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over At Least 52 Weeks in Patients with Progressive Fibrosing	III	1- MASRI CRC, Faculty of Medicine, Ain Shams University /NA 2-CRC, Faculty of Medicine, Alexandria University /NA 3- CRC Air Force Specialized Hospital /NA	Approved 01/06/2023 Withdrawn 17/01/2024	Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)	(Pharmaceutical) BI 1015550 / matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Interstitial Lung Diseases (PF-ILDs) ((FIBRONEER – ILD)		4- CRC, Faculty of Medicine, Cairo University /NA			
66.	06/03/2023	1305-0014 (FIBRONEER – IPF)	Sponsor: Boehringer Ingelheim CRO: IQVIA	A Double Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over At Least 52 Weeks in Patients with Idiopathic Pulmonary Fibrosis (IPF) (FIBRONEER – IPF)	III	1- MASRI CRC, Faculty of Medicine Ain Shams University /NA 2- CRC, Faculty of Medicine, Alexandria University /NA 3- CRC, Air Force Specialized Hospital /NA 4- CRC, Faculty of Medicine, Cairo University /NA	Approved 01/06/2023 Withdrawn 08/01/2024	Idiopathic Pulmonary Fibrosis (IPF)	(Pharmaceutical) BI 1015550 / matching placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

67.	16/03/2023	4202- HEM-201	Sponsor: Forma Therapeutics CRO: MCT	A Phase 2 Open- Label Study to Evaluate Safety and Clinical Activity of FT- 4202 in Patients with Thalassemia or Sickle Cell Disease	II	1- Pediatrics Hematology Department, Abu El-Rich Al Mounira Children Hospital, Cairo University (12/07/2024). 2-CRC, Faculty of Medicine, Cairo University (12/07/2024).	Approved 01/06/2023 Completed 24/09/2025	Thalassemia or Sickle Cell Disease	(Pharmaceutical) Etavopivat
68.	15/05/2023	EFC16035 (PERSEUS)	Sponsor: Sanofi	A Phase 3, Randomized, Double-Blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants with Primary	III	1- CRC, Faculty of Medicine Alexandria University /NA	Approved 10/08/2023 Withdrawn 15/04/2024	Primary Progressive Multiple Sclerosis	(Pharmaceutical) Tolebrutinib/ Matching Placebo

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Progressive Multiple Sclerosis (PERSEUS)					
69.	14/03/2024	WO43571 HereDERA	Sponsor: Roche	A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination with Phesgo Versus Phesgo After Induction Therapy with Phesgo+ Taxane in Patients with Previously Untreated Her2-Positive, Estrogen Receptor-Positive Locally Advanced	III	1- Sohag Oncology Center (19/09/2024) 2- Gustave Roussy International Hospital (19/09/2024) 3- National Cancer Institute - Breast Cancer Treatment & Research Hospital (08/12/2024)	Approved 08/04/2024 Recruitment Completion	Previously Untreated Her2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer	Pharmaceutical Giredestrant

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				or Metastatic Breast Cancer (HereDERA)					
70.	22/04/2024	1517-CL-1003	Sponsor: Astellas Pharma Global Development CRO: MCT	A Phase 3, Open-label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Treatment of Anemia in Pediatric Participants with chronic kidney disease 1517-CL-1003	III	1- Abu Al Rich Al Mounira Children's Hospital, Cairo University /NA 2- MASRI CRC, Faculty of Medicine, Ain Shams University /NA 3- CRC, Faculty of Medicine, Alexandria University /NA	Approved 10/7/2024 Withdrawn 26/09/2024	Anemia in Pediatric Patients with Chronic Kidney Disease	Pharmaceutical Roxadustat

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

71.	05/06/2024	M23-698	Sponsor: Abbvie	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti- TNF Therapy M23-698	III	1- MASRI CRC, Faculty of Medicine, Ain Shams University /NA 2- CRC, Air Force Specialized Hospital /NA 3- CRC, Faculty of Medicine, Alexandria University/NA	Approved 07/08/2024 Withdrawn 09/04/2025	Moderate to Severe Hidradenitis Suppurativa	Pharmaceutical Upadacitinib
72.	16/12/2024	DAY101- 002	Sponsor: Day One Biopharm aceuticals	A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy	III	1- CRC, Children Cancer Hospital Egypt-57357 (16/10/2025).	Approved 19/02/2025	Pediatric Low-Grade Glioma Harboring an Activating RAF	Pharmaceutical Tovorafenib

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			CRO: MCT	Versus Standard of Care Chemotherapy in Patients with Pediatric Low- Grade Glioma Harboring an Activating RAF Alteration Requiring First- Line Systemic Therapy			Recruitment Completion	Alteration Requiring First-Line Systemic Therapy	
73.	29/01/2025	NN7535- 7822 FLORAL	Sponsor: Forma Therapeuti cs CRO: IQVIA	An Open-Label, Multi-Centre, Rollover Study to Characterise Long- Term Safety and Efficacy of Etavopivat in Adults, Adolescents and	III	1- CRC, Faculty of Medicine, Alexandria University /NA 2- Pediatrics Hematology Department, Zagazig University Hospital /NA	Approved 10/04/2025 Recruiting	Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia	Pharmaceutical (Etavopivat)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Children Who Have Sickle Cell Disease or Thalassaemia and Have Completed a Treatment Period in an Etavopivat Study (FLORAL)		3- CRC, Faculty of Medicine, Cairo University (27/08/2025). 4- MASRI CRC, Faculty of Medicine, Ain Shams University /NA 5- Pediatrics Hematology Department, Abu El Rich Al Mounira Children Hospital, Cairo University (27/08/2025)			
74.	16/06/2025	ID-064A301 (OPUS-1)	Sponsor: Idorsia Pharmaceuticals	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-	III	1- CRC Air Force Specialized Hospital /NA 2- CRC, Faculty	Approved 10/08/2025 Withdrawn	Adult Subjects with Moderate to Severe Systemic	Pharmaceutical (Cenerimod)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			CRO: RAY	Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects with Moderate-to- Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy (OPUS-1)		of Medicine, Alexandria University /NA 3- MASRI CRC, Faculty of Medicine, Ain Shams University /NA.	21/01/2026	Lupus Erythematos us	
75.	20/07/2025	MK4482- 0023	Sponsor: MSD	A Phase 3, Randomized, Placebo- Controlled, Double-Blind Clinical Study to	III	1- CRC Air Force Specialized Hospital /NA	Submission Cancellation by EDA 04/11/2025	Non- Hospitalized Adults With COVID-19 at High Risk for	Pharmaceutical (Molnupiravir)

Green	Biological
Blue	Pharmaceutical
Orange	Medical Device
Gray	Innovative
Red	Herbal

				Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults With COVID-19 at High Risk for Disease Progression				Disease Progression	
76.	30/07/2025	1397-0014	Sponsor: Boehringer Ingelheim International GmbH CRO: IQVIA	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for Up to 76 Weeks in Patients With	III	1- Air Force Specialized Hospital CRC /NA 2- CRC, Faculty of Medicine, Alexandria University /NA 3- MASRI CRC, Faculty of Medicine, Ain Shams University /NA	Approved 08/10/2025 Withdrawn 08/02/2026	Bronchiectasis	Pharmaceutical (BI 1291583 2.5 mg)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Bronchiectasis (The AIRTIVITY® Study)					
77.	25/08/2025	D6972C0 0002	Sponsor: Astra Zeneca CRO: IQVIA	A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with	III	1-CRC, Faculty of Medicine, Alexandria University /NA 2- MASRI CRC, Faculty of Medicine, Ain Shams University /NA 3- National Institute of Urology and Nephrology /NA 4- Urology & Nephrology Center, Mansoura University /NA	Approved 11/11/2025 Withdrawn 03/03/2026	Chronic Kidney Disease and High Blood Pressure	Pharmaceutical (Baxdrostat & Dapagliflozin)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Chronic Kidney Disease and High Blood Pressure (Bax-Duo PACIFIC)		5- Urology Department, Specialized Medical Hospital, Mansoura University /NA			
78.	08/09/2025	1378-0041	Sponsor: Boehringer Ingelheim International GmbH CRO: IQVIA	A Phase III Double-Blind, Randomised, Parallel-Group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrost (BI 690517) and Empagliflozin Compared With Placebo and	III	1- CRC, Faculty of Medicine, Alexandria University /NA 2- MASRI CRC, Faculty of Medicine Ain Shams University /NA 3- CRC, Faculty of Medicine, Cairo University /NA	Approved 30/11/2025 Withdrawn 10/12/2025	Type 2 Diabetes, Hypertension and Established Cardiovascular Disease	Pharmaceutical (Vicadrost (BI 690517) and Empagliflozin)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Empagliflozin in Participants with Type 2 Diabetes, Hypertension and Established Cardiovascular Disease					
79.	18/09/2025	AT-01B-008	Sponsor: Atea Pharmaceuticals CRO: AVICEM ER	An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized,	III	1- National Hepatology and Tropical Medicine Institute (NHTMRI) (05/06/2026) 2- CRC Air Force Specialized Hospital /NA	Approved 15/12/2025 Recruiting	Chronic Hepatitis C Virus (HCV)	Pharmaceutical (Bemnifosbuvir-Ruzasvir)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				Controlled, Open-label Study					
80.	18/09/2025	GLOBOT RK	Sponsor: St. Jude Children's Research Hospital CRO: MCT	Phase 2 Study of Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age with NTRK1/2/3 or ROS-1-Fused CNS Tumors (GLOBOTRK)	II	1- CRC, Children Cancer Hospital Egypt 57357 /NA	Approved 18/12/2025	NTRK1/2/3 or ROS-1-Fused CNS Tumors	Pharmaceutical (Entrectinib)
81.	24/07/2022	MD-004	Sponsor: Ezz Medical Industries CRO: Dataclin	Open labelled non randomized self-controlled study to evaluate the safety and performance of Ezvent in hospitalized mechanically ventilated patients	III (pivotal)	1-Critical Care Unit, Kasr Al Aini Hospital, Cairo University (25/10/2022)	Approved 28/08/2022 Suspended 01/01/2024 Resumed 13/01/2024	Hospitalized mechanically ventilated patients	Medical device (Ezvent)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

							Completed 03/06/2025		
82.	15/05/2022	COAV101 B12301	Sponsor: Novartis CRO: MCT	A randomized sham controlled double –blind study to evaluate the efficacy and safety of intrathecal (IT) QAV101 in patients with later onset type 2 spinal muscular atrophy (SMA) who are ≥ 2 to <18 years of age, treatment naïve sitting and never ambulatory	III	1-Department of Neurology, Ain Shams University Specialized Hospital (11/05/2023)	Approved 02/08/2022 Early terminated (by sponsor) 18/12/2023	type 2 spinal muscular atrophy (SMA)	Innovative QAV101 (Zolgensma) (Onasemnogene abeparvovec)
83.	06/06/2023	Urso-003	Sponsor: Minaphar m	Multi-Center, randomized, control, phase IV	IV	1-CRC, Air Force Specialized	Approved 18/09/2023	Compensated Chronic	Innovative

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

			CRO: Dataclin	trial to compare the efficacy & safety of Ursoplus® capsules (UDCA 250mg & Silymarin 140mg) versus UDCA alone versus Placebo among Compensated Chronic Liver Disease Patients		Hospital (01/03/2022) 2-National Hepatology and Tropical Research Institute (NHTMRI) /NA	Suspended (Recruitment suspension) 26/11/2024	Liver Disease Patients	Ursoplus® capsules/ Ursofalk® capsules
84.	06/06/2023	Cipro-001	Sponsor: Minapharm, CRO: Nagy Research	Single center, Open Label, controlled Study to assess the safety & efficacy of Oral Cipro Diazole ® Tablets (Ciprofolxacin/ Metronidazole)	IV	1- General Surgery Department, Menoufia University Hospital. (10/10/2021)	Refusal 12/09/2023 Suspended 12/09/2023	Pelvi-abdominal infections and following IV antibiotics in post-operative period, for	Innovative Cipro Diazole ® Tablets (Ciprofolxacin/ Metronidazole)

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

				versus currently used Ciprofloxacin Tablets & Metronidazole tablets in pelvi-abdominal infections and following IV antibiotics in post-operative period, for pelvi-abdominal surgeries or acute conditions				pelvi-abdominal surgeries or acute conditions	
--	--	--	--	--	--	--	--	---	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

85.	31/07/2023	GRC\ADGE\EG\38\II I	Sponsor: Adwia CRO: Genuine research center (GRC)	A Randomized, Open-label, Active- Controlled Clinical Trial to Investigate the Efficacy and Sa fety of Ondansetron compared to Metoclopramide in the management of Nausea and Vomiting in Adult Patients with Acute Gastroenteritis- (GRC\ADGE\EG\38\ III)	IV	1. Faculty of Medicine, Beni- Suef University Hospital/ NA 2. Faculty of Medicine, Fayoum University Hospital/ NA 3. Faculty of Medicine, Benha University Hospital/ NA	Refusal 28/11/2023	Nausea and Vomiting in Adult Patients with Acute Gastroenteritis	Innovative Ondansetron
-----	------------	------------------------	---	--	----	--	-----------------------	--	-------------------------------

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

86.	24/10/2023	GRC/NE-CV/EG/39/IV	Sponsor: Nerhadou International CRO: Genuine research center	A prospective, Multicentre, Open-label, Single-arm Interventional Study of Bisoprolol (Nerkardou) (Between Low Dose and High Dose) 5 and 10 mg ODF Treatment in Egyptian Patients with Essential Hypertension	IV	1- Department of General Internal Medicine, Beni-Suef University Hospital (22/10/2024) 2- Department of Cardiology and Vascular Medicine, Fayoum University Hospital (07/08/2024)	Approved 10/03/2024 Terminated by sponsor 13/05/2025	Essential Hypertension	Innovative Nerkardou (Bisoprolol) Oral dispersible film
-----	------------	--------------------	---	---	----	--	---	------------------------	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

87.	13/08/2025	START24 042025	Sponsor: Eva Pharma CRO: MARC	Adhesion and Safety of Rotigexole Compared to Neupro®: A Non- Inferiority Open- Labelled Crossover Randomized Controlled Trial.	IV	1- MARC CRC (09/02/2026) 2- Department of Neurology, Ain Shams Specialized Hospital (26/02/2026) 3- Department of Neurology, Al Manial Specialized Hospital, Cairo University (29/03/2026)	Approved 12/11/2025	Parkinson's Disease	Innovative Rotigotine 8 mg/24h Transdermal Patch
-----	------------	-------------------	---	---	----	--	------------------------	------------------------	---

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

88.	25/08/2024	NW- Roselle- 572023	Sponsor: Natural wellness CRO: Clinmax	Efficacy and safety of Roselle in phase III, randomized, double -blind, double dummy, active controlled clinical trial	III	1- Cardiology Department, Faculty of Medicine, Alexandria University Hospitals/NA 2- Cardiology Department Faculty of Medicine, Mansoura University Hospitals/NA 3- Fayoum General Hospital/NA	Refused 15/01/2025	Hypertension	(Herbal) Hibiscus sabdariffa, Olea europaea L
-----	------------	---------------------------	--	--	-----	---	-----------------------	--------------	--

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal

89.	02/09/2024	NW_LowGlu_18052023	Sponsor: Natural wellness CRO: Dataclin	A Phase III, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients with Type II Diabetes Mellitus	III	1- Internal Medicine Department, Faculty of Medicine, Alexandria University/NA 2- Internal Medicine Department, Faculty of Medicine, Alazahar University/NA 3- Internal Medicine Department, Imbaba General Hospital/NA	Refused 22/05/2025	Type II Diabetes Mellitus	(Herbal) Mas Cotek powdered Extract 300 mg Cinnamomum cassia, Black seed powdered extract 250 mg)
-----	------------	--------------------	--	--	-----	---	-----------------------	---------------------------	---

Color Indicator	Green	Biological
	Blue	Pharmaceutical
	Orange	Medical Device
	Gray	Innovative
	Red	Herbal